Rodrigo Cristofoletti, Ph.D., is Assistant Professor of Pharmacometrics and Systems Pharmacology and Associate Director of Centre for Pharmacometrics and Systems Pharmacology, University of Florida, USA.Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX, FBPS, is Professor of Systems Pharmacology and Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK and SVP of R&D, Chief Scientific Officer (CSO), Certara, Princeton, USA.

• 1. From A Mathematical Model to a Technology, the 100 Years’ Evolution of PBPK 2. Basic principles of PBPK modeling and simulation 3. Oral Drug absorption in special populations: in vivo – in vitro – in silico evaluation 4. Physiologically based absorption models for complex formulations and dosage forms 5. Perfusion and permeability-limited distribution models 6. Modeling drug metabolism and excretion7. Platform Qualification and Model verification8. Applying PBPK modeling to predict drug-drug interactions9. Applying PBPK modeling to predict drug exposure in special populations10. PBPK-based Virtual Bioequivalence Trials to Guide Drug Development11. Application of PBPK modeling to support clinical pharmacology regulatory decision-making12. Physiologically based biopharmaceutics modeling (PBBM) in support of drug product specifications and biowaiver13. Integrating PBPK modeling and Organ-on-a-chip systems to inform drug development

Rodrigo Cristofoletti, Ph.D., is Assistant Professor of Pharmacometrics and Systems Pharmacology and Associate Director of Centre for Pharmacometrics and Systems Pharmacology, University of Florida, USA.Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX, FBPS, is Professor of Systems Pharmacology and Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK and SVP of R&D, Chief Scientific Officer (CSO), Certara, Princeton, USA.

• 1. From A Mathematical Model to a Technology, the 100 Years’ Evolution of PBPK 2. Basic principles of PBPK modeling and simulation 3. Oral Drug absorption in special populations: in vivo – in vitro – in silico evaluation 4. Physiologically based absorption models for complex formulations and dosage forms 5. Perfusion and permeability-limited distribution models 6. Modeling drug metabolism and excretion7. Platform Qualification and Model verification8. Applying PBPK modeling to predict drug-drug interactions9. Applying PBPK modeling to predict drug exposure in special populations10. PBPK-based Virtual Bioequivalence Trials to Guide Drug Development11. Application of PBPK modeling to support clinical pharmacology regulatory decision-making12. Physiologically based biopharmaceutics modeling (PBBM) in support of drug product specifications and biowaiver13. Integrating PBPK modeling and Organ-on-a-chip systems to inform drug development

Rodrigo Cristofoletti, Ph.D., is Assistant Professor of Pharmacometrics and Systems Pharmacology and Associate Director of Centre for Pharmacometrics and Systems Pharmacology, University of Florida, USA.Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX, FBPS, is Professor of Systems Pharmacology and Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK and SVP of R&D, Chief Scientific Officer (CSO), Certara, Princeton, USA.

• 1. From A Mathematical Model to a Technology, the 100 Years’ Evolution of PBPK 2. Basic principles of PBPK modeling and simulation 3. Oral Drug absorption in special populations: in vivo – in vitro – in silico evaluation 4. Physiologically based absorption models for complex formulations and dosage forms 5. Perfusion and permeability-limited distribution models 6. Modeling drug metabolism and excretion7. Platform Qualification and Model verification8. Applying PBPK modeling to predict drug-drug interactions9. Applying PBPK modeling to predict drug exposure in special populations10. PBPK-based Virtual Bioequivalence Trials to Guide Drug Development11. Application of PBPK modeling to support clinical pharmacology regulatory decision-making12. Physiologically based biopharmaceutics modeling (PBBM) in support of drug product specifications and biowaiver13. Integrating PBPK modeling and Organ-on-a-chip systems to inform drug development